Adial Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview

Adial Pharmaceuticals

08/11/2024 15:48

* Adial Pharmaceuticals Inc  ADIL.OQ   ADIL.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 12 (estimated) for the period ending January 1 0001
    * 
    * ​LSEG's mean analyst estimate for Adial Pharmaceuticals
Inc is
for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adial
Pharmaceuticals Inc is 7.50​, above​ its last closing price
of $1.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.53       -0.53      -0.59     Missed  -10.3
 Mar. 31 2024  -0.33       -0.33      -0.62     Missed  -87.9
 Jan. 1 0001   -0.89       -0.76      -1.35     Missed  -77.6​
 Sep. 30 2023  -1.13       -1.13      -1.18     Missed  -4
 ​​Jun.        -1.46       -1.50      0.96      Beat    164
 30 2023                                                
 Jan. 1 0001   -3.50       -3.50      -2.75     Beat    21.4​
 Jan. 1 0001   -3.75       -3.75      -2.75     Beat    26.7
 Sep. 30 2022  -4.75       -4.50      -3.00     Beat    33.3
 This summary was machine generated November 8 at 15:48 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)